Peregrine Pharmaceuticals Begins Dosing in Phase II Trial of Bavituximab
Peregrine Pharmaceuticals has announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.
The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial of bavituximab in non-small cell lung cancer patients.
The primary objective of the new breast cancer study is to assess the overall tumor response rate to the combination of bavituximab with carboplatin and paclitaxel.
Steven King, president and CEO of Peregrine, said: “The combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel performed well in an earlier Phase I study, and we look forward to learning more about bavituximab’s potential in this larger breast cancer study. With three Phase II studies now underway, we look forward to significant clinical data being generated throughout the rest of this year.”